EcoDrugPlus

Cholecystokinin Receptor-Like

Ensembl ID : ENSSLDG00000003311
Gene Symbol: LOC111646049
3 Cross references
193 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSSLDG00000003281
Gene Symbol: LOC111672518
3 Cross references
258 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSSLDG00000013936
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSSLDG00000018456
Gene Symbol: CHRM2
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSSLDG00000024692
Gene Symbol: CHRM2
3 Cross references
185 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSLDG00000015878
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSLDG00000014782
Gene Symbol: CHRM3
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSLDG00000015668
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSSLDG00000023148
Gene Symbol: CHRM5
3 Cross references
189 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSLDG00000001731
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSLDG00000014720
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSLDG00000001742
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).